Albers Jeffrey W.
CIK 0001638474 Name as filed on the most recent filing
Filed as Albers Jeffrey W. (64)
162 transaction lines · from 64 filings · filed 2015-11-04 to 2026-08-10 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER Spyre Therapeutics, Inc. 3 filings
- ISSUER Kymera Therapeutics, Inc. 6 filings
- ISSUER Blueprint Medicines Corp 55 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
162 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-07 |
Spyre Therapeutics, Inc. SYRE |
S, Open-market sale | 10,000 disposed | 104.68 | 1,046,800.00 | Form 4, filing 0001636282-26-000102 | |
| 2026-08-07 |
Spyre Therapeutics, Inc. SYRE |
S, Open-market sale | 8,000 disposed | 104.38 | 835,040.00 | Form 4, filing 0001636282-26-000102 | |
| 2026-08-07 |
Spyre Therapeutics, Inc. SYRE |
S, Open-market sale | 5,000 disposed | 104.47 | 522,350.00 | Form 4, filing 0001636282-26-000102 | |
| 2025-12-08 |
Kymera Therapeutics, Inc. KYMR |
S, Open-market sale | 2,748 disposed | 89.32 | 245,459.60 | Form 4, filing 0001193125-25-311505 | |
| 2025-12-08 |
Kymera Therapeutics, Inc. KYMR |
S, Open-market sale | 2,252 disposed | 90.30 | 203,363.48 | Form 4, filing 0001193125-25-311505 | |
| 2025-10-13 |
Kymera Therapeutics, Inc. KYMR |
S, Open-market sale | 5,000 disposed | 59.19 | 295,949.00 | Form 4, filing 0001193125-25-238130 | |
| 2025-06-03 |
Kymera Therapeutics, Inc. KYMR |
S, Open-market sale | 6,349 disposed | 49.00 | 311,101.00 | Form 4, filing 0000950170-25-081198 | |
| 2025-05-27 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 4,350 disposed | 101.02 | 439,437.00 | Form 4, filing 0001415889-25-014862 | |
| 2025-05-27 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 650 disposed | 101.93 | 66,254.50 | Form 4, filing 0001415889-25-014862 | |
| 2025-03-12 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 5,700 disposed | 87.62 | 499,434.00 | Form 4, filing 0001415889-25-008112 | |
| 2025-03-12 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 1,800 disposed | 88.37 | 159,066.00 | Form 4, filing 0001415889-25-008112 | |
| 2025-03-05 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 5,766 disposed | 88.80 | 512,020.80 | Form 4, filing 0001415889-25-008211 | |
| 2025-01-21 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 7,561 disposed | 109.11 | 824,980.71 | Form 4, filing 0001415889-25-001989 | |
| 2025-01-21 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 7,400 disposed | 109.92 | 813,408.00 | Form 4, filing 0001415889-25-001989 | |
| 2025-01-21 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 200 disposed | 110.61 | 22,122.00 | Form 4, filing 0001415889-25-001989 | |
| 2025-01-13 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 5,000 disposed | 102.28 | 511,400.00 | Form 4, filing 0001415889-25-001507 | |
| 2024-12-19 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 5,180 disposed | 89.01 | 461,071.80 | Form 4, filing 0001415889-24-029971 | |
| 2024-12-19 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 3,920 disposed | 88.28 | 346,057.60 | Form 4, filing 0001415889-24-029971 | |
| 2024-12-19 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 3,800 disposed | 91.15 | 346,370.00 | Form 4, filing 0001415889-24-029971 | |
| 2024-12-19 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 2,100 disposed | 91.96 | 193,116.00 | Form 4, filing 0001415889-24-029971 | |
| 2024-11-07 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 5,000 disposed | 102.00 | 510,000.00 | Form 4, filing 0001415889-24-026594 | |
| 2024-11-06 |
Spyre Therapeutics, Inc. SYRE |
S, Open-market sale | 6,700 disposed | 36.76 | 246,312.77 | Form 4, filing 0001636282-24-000089 | |
| 2024-10-25 |
Spyre Therapeutics, Inc. SYRE |
S, Open-market sale | 300 disposed | 36.43 | 10,929.00 | Form 4, filing 0001636282-24-000070 | |
| 2024-09-09 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 11,968 disposed | 85.86 | 1,027,572.48 | Form 4, filing 0001415889-24-023204 | |
| 2024-09-09 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 7,734 disposed | 85.12 | 658,318.08 | Form 4, filing 0001415889-24-023204 | |
| 2024-08-26 |
Kymera Therapeutics, Inc. KYMR |
S, Open-market sale | 5,000 disposed | 49.10 | 245,508.50 | Form 4, filing 0000950170-24-100660 | |
| 2024-03-20 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 8,440 disposed | 87.26 | 736,474.40 | Form 4, filing 0001415889-24-009009 | |
| 2024-03-20 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 6,285 disposed | 88.60 | 556,851.00 | Form 4, filing 0001415889-24-009009 | |
| 2024-03-20 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 6,251 disposed | 86.46 | 540,461.46 | Form 4, filing 0001415889-24-009009 | |
| 2024-03-20 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 2,730 disposed | 85.22 | 232,650.60 | Form 4, filing 0001415889-24-009009 | |
| 2024-03-20 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 1,367 disposed | 89.12 | 121,827.04 | Form 4, filing 0001415889-24-009009 | |
| 2024-03-07 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 11,033 disposed | 90.69 | 1,000,582.77 | Form 4, filing 0001415889-24-009169 | |
| 2024-02-21 |
Kymera Therapeutics, Inc. KYMR |
S, Open-market sale | 4,385 disposed | 39.05 | 171,226.80 | Form 4, filing 0000950170-24-018246 | |
| 2024-02-20 |
Kymera Therapeutics, Inc. KYMR |
S, Open-market sale | 615 disposed | 39.07 | 24,030.88 | Form 4, filing 0000950170-24-018246 | |
| 2024-01-25 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 10,890 disposed | 81.70 | 889,713.00 | Form 4, filing 0001415889-24-001931 | |
| 2024-01-25 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 7,924 disposed | 82.76 | 655,790.24 | Form 4, filing 0001415889-24-001931 | |
| 2024-01-25 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 6,086 disposed | 81.16 | 493,939.76 | Form 4, filing 0001415889-24-001931 | |
| 2024-01-25 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 100 disposed | 83.57 | 8,357.00 | Form 4, filing 0001415889-24-001931 | |
| 2024-01-23 |
Kymera Therapeutics, Inc. KYMR |
S, Open-market sale | 10,000 disposed | 30.05 | 300,470.00 | Form 4, filing 0000950170-24-006766 | |
| 2023-12-11 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 5,000 disposed | 79.07 | 395,350.00 | Form 4, filing 0001415889-23-016360 | |
| 2023-11-30 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 5,000 disposed | 70.55 | 352,750.00 | Form 4, filing 0001415889-23-015737 | |
| 2023-11-24 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 7,964 disposed | 67.25 | 535,579.00 | Form 4, filing 0001415889-23-015539 | |
| 2023-11-24 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 7,036 disposed | 67.81 | 477,111.16 | Form 4, filing 0001415889-23-015539 | |
| 2023-11-03 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 1,485 disposed | 60.13 | 89,293.05 | Form 4, filing 0001415889-23-014779 | |
| 2023-11-02 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 4,575 disposed | 60.36 | 276,147.00 | Form 4, filing 0001415889-23-014779 | |
| 2023-11-02 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 59 disposed | 61.05 | 3,601.95 | Form 4, filing 0001415889-23-014779 | |
| 2023-11-01 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 3,881 disposed | 60.02 | 232,937.62 | Form 4, filing 0001415889-23-014779 | |
| 2023-09-28 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 6,898 disposed | 50.17 | 346,072.66 | Form 4, filing 0001415889-23-013648 | |
| 2023-09-27 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 12,102 disposed | 49.93 | 604,252.86 | Form 4, filing 0001415889-23-013648 | |
| 2023-09-27 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 5,600 disposed | 48.84 | 273,504.00 | Form 4, filing 0001415889-23-013648 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 0
- Open-market sale 162
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. Albers Jeffrey W., insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001638474
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6